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Abstract: This systematic review with metanalysis evaluated and analyzed the beneficial effects of
certain plants food in type 2 diabetes (T2D) when consumed alone or in combination with chitosan.
The main objective of the paper was to examine the relation of chitosan nanogel and mixed food
plant (MFP) to control T2D. The databases included Medline, Scopus, PubMed, as well as Cochrane
available between the month of January 1990 to January 2021. The eligibility criteria for selecting
studies were case-controlled studies that included unripe plantain, bitter yam, okra, and chitosan
either used-alone or in combination with non-specified food plants (NSFP). Two-fold autonomous
critics retrieved the information required and evaluated the risk of bias of involved studies. Randomeffect meta-analyses on blood glucose controls, were performed. Results of 18 studies included: seven
that examined unripe plantains, one bitter yam, two okras, and eight chitosan, found regarding the
decrease in blood glucose level. Meta-analysis of the results found a large proportion of I2 values
for all studies (98%), meaning heterogeneity. As a consequence, the combined effect sizes were not
useful. Instead, prediction interval (PI) was used (mean difference 4.4 mg/dl, 95% PI −6.65 to 15.50
and mean difference 3.4 mg/dl, 95% PI −23.65 to 30.50) rather than the estimate of its confidence
interval (CI). These studies were at 50% high risk of bias and 50% low risk of bias and there was
judged to be an unclear risk of bias due to the insufficient information from the included study
protocol (moderately low). The intervention lasted between three and 84 days, indicating potency
and effectiveness of the intervention at both short and long durations. Due to the moderately low
quality of the studies, the findings were cautiously interpreted. In conclusion, the current evidence
available from the study does support the relation of chitosan with mixed unripe plantain, bitter
yam and okra for the management of T2D. Further high-quality case-controlled animal studies are
required to substantiate if indeed chitosan nanogel should be cross-linked with the specified food
plant (SFP) for the management T2D.
Keywords: T2D; unripe plantain; bitter yam; okra; chitosan; case-controlled study
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Hyperglycemia that leads to T2D appears to represent a persistent set of life-sustaining
chemical conditions which is described by elevated blood sugar which manifests well as the
inadequate and ineffective release of pancreatic hormone and affects a set of life-sustaining
chemicals, such as glucose amino acids and fatty acids [1]. Data show that in 2015 more
than 400 million adults globally were affected by this condition. These people were
predominantly among the economically disadvantaged population, and T2D is projected to
be the seventh leading cause of death by 2030 [1]. T2D in contrast to type 1 diabetes (T1D)
does not completely rely on insulin. T2D is a metabolic condition largely described for its
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role in licking the cell membrane, low release of the pancreatic hormone-insulin, as well as
the upsurge of blood sugar upon directly ingesting food [1,2].
In third world countries and globally, the predominance of T2D is ascribed to the
modifications in lifestyle, including the transition from home prepared food high in phytonutrients (i.e., Polyphenols) to a more Westernized type of food which might be considered less nutritionally sound [3]. Such lifestyle changes have resulted in the increase of the
prevalence of prolonged and deteriorating diseases.
The therapeutic benefits of customary foods have assumed significant place lately as a
result of benefits connected to their phytonutrients [4,5]. Legumes as well as other food
plants possess significant benefits in preventing as well as managing prolonged diseases [4].
Table 1 presents the characteristics of the most frequent drugs used for T2D.
Table 1. Showing characteristics of common antidiabetic drugs used for T2D treatment.
Class of Antidiabetic Drug

Specific Mechanism of Action

Adverse Effect

Reference

Acabose—Used for treating T2D

Acarbose works by slowing down
the action of certain chemicals
that break down food to release
glucose into the blood; slow food
digestion helps to keep blood
glucose from rising high after
any meal.

Hyperglycemia, Shaking,
Dizziness, Sweating, Irritability,
Mood change, Headache,
Numbness, Weakness, Pale skin,
Hunger, Clumsy, Confusion,
Seizures, Loss of consciousness,
Extreme thirst, Frequent
urination, Blurred vision, Dry
mouth, Stomach upset, Vomiting,
Shortness of breath, Breath that
smells fruity and
decreased consciousness.

[6]

Voglibose—Used as an α-glucosidase
inhibitor that manages postprandial
blood sugar in T2D.

α-glucosidase inhibitor; the
saccharides, acting as competitive
inhibitor of enzymes needed to
digest carbohydrate specifically
the α–glucosidases enzymes
present in brush border of
small intestine.

Seen in about 25% of users.
Adverse effects include: Soft stool,
Diarrhoea, Flatulence, Bloating,
Abdominal pain or fullness
and nausea.

[7]

Glyset (Miglitol)—A drug employed to
treat symptoms of T2D. It can be used
alone or in combination with this class of
drugs. It belongs to a class of drugs
referred to as Antidiabetics,
α-glucosidase inhibitors.

Unlike Sulonylureas, Glyset
(Miglitol) does not enhance
insulin secretion.
Antihyperglycemia action of
Miglitol results from a reversible
inhibition of membrane-bound
intestinal α-glucosidase hydrolase
enzymes.

Hives, Difficulty breathing,
swelling of the face, Lips, Tongue,
or throat, Severe diarrhea,
Constipation, Bloody or tarry
stools, rectal bleeding and
diarrhea that contains blood
or mucus.

[8]

Biguanides—This refers to a group of
oral diabetes drugs that work by
preventing the production of sugar in the
liver, improving the body sensitivity
towards insulin and reducing the amount
of sugar absorbed by the intestines.

It works by preventing the liver
from converting fat and amino
acids into sugar. They also
activate an enzyme which helps
cells respond more effectively to
insulin and takes in sugar from
the blood. It is used by obese
people as it promotes weight loss.

Hypoglycemia results very rarely,
weight gain and digestive adverse
reactions.

[9]

Thiazolidinedione (TZDs)—These are
insulin sensitizers that act on intercellular
metabolic pathways to enhance insulin
action and increase sensitivity in
critical tissues.

TZDs act by activating
peroxisome proliferator-activated
receptors. They are also agonist.
The endogenous ligands for those
receptors which are fatty acids
and eicosanoids. This binds DNA
when receptors activated.

Increase hepatitis and possible
liver failure, Edema, Heart failure,
Coronary Heart Disease (CHD),
Plaque progression, Myocardia

[9]
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Table 1. Cont.
Class of Antidiabetic Drug

Specific Mechanism of Action

Adverse Effect

Reference

Sulfonylureas—Stimulates the release of
insulin from pancreatic Beta-cells and
have a number of extra-pancreatic effects

Induces sugar
independent-insulin release from
Beta-cells by inhibiting potassium
flux through Adenosine
Triphosphate (ATP) dependent
potassium channels.

Hypoglycemia, Induces
hyponatremia, Edema, Induces
alcohol flushing.

[10]

Meglitinides—these are oral drugs used
for T2D. They work by triggering
production of insulin.

Meglitinide (Rpaglinide)—This is
an insulin secretagogue meaning
that it binds to receptors on
pancreatic beta-cells and
stimulates insulin release.
Repaglinide binds to an
ATP-dependent potassium
channel on beta-cells.

Hypoglycemia (low blood sugar)
is associated with increased
mortality and weight gain

[9]

Synthetic medications, e.g., acarbose, viglibose, and miglitol, are alfa-glucosidase
inhibitors while others include biguanides, thiazolidinediones, sulphonylureas, and meglitinides, which display discomforting side effects, such as stomach pain, swelling, the release
of ammonia gas from digestion, swelling of the stomach caused by dwelling gas, as well
as the loss of fluid via the elementary canal [9]. Some of these discomforting symptoms
are perhaps triggered by the production of ethanol as a result of the increased presence of
bacteria; an end product from non-catabolized carbohydrates in the gastro intestinal (GI)
track. Foods from plant sources generally comprise natural antioxidants such as phenolic
compounds that can scavenge for ROS also referred to as free radicals [11–17].
With the use of new oral antidiabetics (OAD), such as gliptines, glucagon-like peptide1 (GLP-1) analogues, gliflozines were approved for the treatment of T2D, demonstrating
improved glycemic control, weight loss, and cardiovascular benefit [7]. The fruit content of
plantain (Musa paradisiaca) is considered a major food product in Africa which provides
a great source of energy for these people. Plantains are stated as an essential basis for
pro-retinoids around continents (Asia, Africa, as well as Latin America).
Musa parasidiaca is rich in fat-soluble retinoids, water soluble B vitamins (thiamin,
niacin, riboflavin and pyridoxine), and vitamin C. This food is discovered to be extremely
rich in potassium but poor in sodium. Musa parasidiaca is an excellent source for vit A
compared to other foods. Fat-soluble vit A (carotenoid) is considered to a safeguard against
diabetes, heart disease, and cancer. The fat-soluble vitamin is among the best essential
groups of phytonutrients which exhibit a vital role in the nutritious value of the plants.
Plantain has been used in Nigeria to decrease blood sugar levels after a carbohydrate (CHO)
meal. Plantain fits into the family of flowering plants eaten ripe or unripe using diverse
methods of processing techniques, being cooked as well as fried. Additionally, products,
such as flour and chips, have been made from plantain [10].
Bitter yam (Dioscorea dumetorum) is a food commonly used in tropical countries.
This short (small) tuber fits into Dioscorea family. Collectively, it is referred to as bitter yam
trifoliate (three–leaved) yam. It is believed to promote glucose balance for the diabetics
and to be a therapeutic remedy for different diseases [18,19] Moreover, in the middle-belt
region of Nigeria, the Tiv speaking tribe refers to it as ‘Anube’ used for consumption and
medicinal purposes to treat illnesses [19].
Okra is unique as a flowering plant of the mallow family [13]. The okra fruit is
eaten as a common plant in several nations (including Nigeria and Cyprus). It is rich
in nutrients. Okra is known for its therapeutic importance, particularly in respect to
lowering the blood glucose effect. While okra is usually seen as a plant that is beneficial to
diabetic patients, a limited number of technical articles have acknowledged the therapeutic
function that okra performs. Earlier research of Sabitha showed that okra oil extracts
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promoted hypoglycemic and low-fat beneficial effects, as well as improved the weight
in Streptozotocin (STZ)-induced diabetic rats. Having a better anti oxidation capability,
okra is known to reduce the oxidation of lipids, as well as raise the amount of Superoide
Dismutase (SOD), Chloramphenicol acetyltransferase (CAT), as well as Glutathione (GSH).
It is worth mentioning that decreased levels of GSH were found in the diabetic rats [9].
A useful food can be defined as food which delivers both nutritional and physiological
supports to organisms or decreases the possibility of protracted ailments [16]. Okra fruit [17]
has previously been shown to establish lower blood sugar as well as lower lipid actions,
becoming a versatile and remarkable substitute to control hyperglycemia.
Nanoparticle production procedures can be easily performed as well as valid amidst
wide variable medications. In these systems of delivering medication, polymeric nanoparticles have increased their significance, being eco-friendly, biocompatible, and due to their
process of preparation much broadly obtainable. Hence, the variety of uses has been increasing to comprise a multiplicity of chemical medication groups and quantity systems [20,21].
Chitosan-based nanoparticles are mostly suitable and less toxic. Chitosan nanogel has been
applied to manage production and the spreading of cell in the body, gastrointestinal tract
disorders (GIT) disorder, heart disorder, and channeling medication reaching the central
nervous system as well as eye impurities. New investigations in nanogel for oral medication
(pills, capsules, syrups) have been centered around premises that increased acceptability of
nanogel characteristics as well as techniques involving biochemical changes can be useful
in specific nanogel therapeutic production as well as distribution structures. Chitosan is
considered as one of the key derived products of chitin, made by eliminating the acetate
part from chitin. It is a derivative of crustacean shells, such as those from prawns or crabs,
and cell walls of organisms such as fungi. Its occurrence is natural as a polysaccharide. As a
cation, extremely basic in nature, Chitin is obtained naturally, linked with peptides as well
as elements that require detachment before the preparation of chitosan; hence, the methods
of acidifying and alkalizing. After purification, acetyl groups are removed from chitin and
substituted with amino group to produce chitosan. Nanogel acts in diffusing the openings
of tight junctions of epithelium, enhancing the healing of wounds. Chitosan eases both the
transport of therapies between and through cells. Chitosan relates with secretions which are
negatively charged to bring about complex hydrophobic (water-hating) interrelationships.
The acidic content in the primary amino group of nanogel is 6.5, similar to the amount of
acetyl free linked amino group. Likewise, this class of acids aids the dissolving of nanogel
hydrogen ion systems as well as the incomplete deactivation of primary amines, which
could possibly elucidate the reason why chitosan has been described as concentrating acid
from neutral to high hydrogen ion concentration [22]. Therefore, the user of nanoparticles
is required to cautiously bring together the preferred chemical and physical characteristics
of the chitosan, as well as the expected bio-system, using the chitosan treatment technique.
With this scientific evidence regarding the specified plant food (SFP), unripe plantain,
bitter yam, and okra so far, the need to use them for the management of T2D has been
limited to combining them alone [3,15,23–25] or in combination with NSFP [2,5,26–28],
and those used separately or in combination are not cross-linked with chitosan [7,10,29].
However, where there is a cross-linkage with chitosan, those linkages are not with the
SFP [30–33] (Table 2).
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Table 2. Food plants and chitosan used for their therapeutic and benefit in T2D.
Food Plant and Chitosan

Therapeutic Use

•
•
Unripe plantain (Musa paradisiaca)

Food plant was used alone.
Exert anti-hyperglycemic effects due to the inhibition of
α-amylase and α-glucosidase activities by their
essential phytochemicals as well as their
amylose/amylopectin contents in diabetic rats.

Benefits/Nutritional Value

•
•

•

•
Unripe plantain (Musa paradisiaca); soya
bean cake and cassava fibre.

•

Used in combination.

•
•
•

Used in combination.
Anti-hyperglycemic and and anti-hyperlipemic effect.
The M. paradisiaca-based diet significantly (p < 0.05)
overturned the levels of fasting blood glucose, with
significant (p < 0.05) increase in insulin and glycogen
concentrations.
The diet also increased the activity of hexokinase with
significant reduction (p < 0.05) in glucose-6-phosphatase
and fructose-1-6-diphosphatase activities.

•

•

Unripe plantain (Musa paradisiaca) and
(Dioscorea rotundata)

•

•
•
Unripe plantain (Musa paradisiaca)

•
•
•
Unripe plantain (Musa paradisiaca L.);
cocoyam (Colocasia esculenta L.).

•

Used alone.
The hyperglycemic mice needed vital modification (p <
0.05) with hyperglycemia.
Unripe plantain could play a key role in diabetes
management.
Used in combination.
Feeding of rats with test feeds for 21 days to the
diabetic rats of groups (Grps) 4 and 5, brought about
58.75% and 38.13% reductions in hyperglycemia.
Cocoyam and Musa parasidiaca can management of
hyperglycemic kidney disease.

•

•

•
•
•

•

Reference

Source of nutrients vital to human well-being
i.e., Moisture, Crude protein, Crude lipid, Ash,
Crude fiber, Carbohydrate, and gross energy
148.6 Kcal/100 g.
Mineral content of sodium, Potassium, Calcium,
Magnesium, Iron, Phosphorus, Zinc, Manganese,
and Copper

[3,34]

Moisture, Crude protein, Crude lipid, Ash, Crude
fiber, Carbohydrate, and gross energy
148.6 Kcal/100 g.
Mineral content of sodium, Potassium, Calcium,
Magnesium, Iron, Phosphorus, Zinc, Manganese,
and Copper

[23,34]

Moisture, Crude protein, Crude lipid, Ash, Crude
fiber, Carbohydrate, and gross energy
148.6 Kcal/100 g.
Mineral content of Sodium, Potassium, Calcium,
Magnesium, Iron, Phosphorus, Zinc, Manganese,
and Copper.
Diocorea rotundata; a family of the Dioscorea
contains similar nutritional value such as
Flavonoids, Alkaloids, Saponins.
Cardiac glycosides are present in small quantities.
Tannins and anthraquinones are absent.

[22,34,35]

Moisture, Crude protein, Crude lipid, Ash, Crude
fiber, Carbohydrate, and gross energy
148.6 Kcal/100 g.

[5,34]

Moisture, Crude protein, Crude lipid, Ash, Crude
fiber, Carbohydrate, and gross energy
148.6 Kcal/100 g.

[34,36]

Nutrients 2022, 14, 4710

6 of 33

Table 2. Cont.
Food Plant and Chitosan

Therapeutic Use

•
•

•
Unripe plantain (Musa paradisiaca L.); soya
bean cake and rice bran.

•

•

Unripe plantain (Musa paradisiaca L.), Ginger
(Zingber officinale).

•

•
Bitter yam (Dioscorea batatas)

Used in combination.
The dough meals decreased blood glucose by
approximately 76% in diabetic rats stabilizing at the
same time the lipid profiles to normal physiological
range.
The combination of plantain, soybean cake and rice
bran was able to yield functional dough with good
nutritional composition, pasting properties, and
antidiabetic potential; decreasing serum glucose of
diabetic rats by more than 70%.
The formulated functional dough considered promising
diet that can be recommended for patients with low
economic status suffering from diabetes, especially in
Sub-Saharan Africa.
Used in combination with Group iii as well as vi mice
needed 159.52 percent as well as 71.83 percent
reductions in blood glucose; however, 24.91 percent as
well as 35.32 percent reductions regards heaviness
related to group I as well as ii mice which needed
2.09 percent as well as 22.94 percent upsurge in blood
glucose by 13.42 percent rise with 45.36 percent
reductions via weightiness separately.
Combination of Musa parasidiaca as well as Zingiber
officiale whose dosage needed for controlling
hyperglycemia remained imprecise related with Musa
parasidiaca unaided.
Used alone. The results show that yam and allantoin
(another component inside bitter yam) have
antidiabetic effects by controlling antioxidant activities,
lipid profiles and by promoting the release of GLP-1,
thereby improving the function of β-cells maintaining
normal insulin and glucose levels.

Benefits/Nutritional Value

•

•

•

•
•

Reference

Moisture, Crude protein, Crude lipid, Ash, Crude
fiber, Carbohydrate, and gross energy
148.6 Kcal/100 g.

[27,34]

Moisture, Crude protein, Crude lipid, Ash, Crude
fiber, Carbohydrate, and gross energy
148.6 Kcal/100 g

[4,34]

Diocorea batatas; a family of the Dioscorea contains
similar benefit nutritionally such as Flavonoids,
Alkaloids, Saponins.
Cardiac glycosides are present in small quantities.
Tannins and anthraquinones are absent along rich
mineral elements.

[22,37]
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Table 2. Cont.
Food Plant and Chitosan

Therapeutic Use

•

Okra (Abelmoschus esculentus)

•

•
•
•

•
Okra (Abelmoschus esculentus)

•

•

•
•

Chitosan

•

•

Used alone. Fruits and seeds, but significantly (p < 0.05)
reduced the total phenolic content as well as their free
radical scavenging capacity.
Regular administration of processed and untreated fruit
(UTF) and seed suspensions significantly reduced (p <
0.05) the blood glucose level of rats.
Boiling and roasting do not significantly affect the
antidiabetic potential of A. esculentus fruits and seeds.
Used alone.
Serum glucose sharply increased and insulin resistance
was noted in the diabetic rats (glucose: 360–500 mg/dl,
Homeostasis model of assessment for insulin resistance
(HOMA-IR) 9.8–13.8).
F2 preparation, rich in polysaccharides and
carbohydrates, was most effective in reducing
hyperglycemia and insulin resistance (glucose:
200 mg/dl; HOMA-IR: 5.3) and especially HbA1C
(from 8.0% to 6.5%).
All of the Okra subfractions reduced the level of
triglycerides and free fatty acid, but not the level of
total cholesterol.
Whether it is consumed as a vegetable or as a
nutraceutical, Okra has the potential to be an
alternative therapy for diabetes.
Used alone without cross-linking the SFP.
The palmityl acylated exendin-4 (Ex4-C16) release from
deoxycholic acid-modified glycol chitosan (DOCA-GC)
nanogels was seriously delayed against Ex4.
DOCA-GC nanogels were deposited quickly after
pulmonary administration and persisted in the lungs
for approximately 72 h.
The hypoglycemic period of inhaled Ex4-C16 nanogels
was much better than that of Ex4 nanogels in db/db
mice.

Benefits/Nutritional Value

•

•

•
•

Reference

Source of nutrients that are vital to human
well-being, e.g., vitamins, potassium, calcium,
carbohydrates, dietary fiber, and unsaturated fatty
acids like linolenic and oleic acids, and similarly of
bioactive chemicals.

[24,38]

Source of nutrients that are vital to human
well-being, e.g., vitamins, potassium, calcium,
carbohydrates, dietary fiber, and unsaturated fatty
acids like linolenic and oleic acids, and similarly of
bioactive chemicals.

[15,38]

Chitosan enhances the healing of wounds.
Chitosan also eases both transport of medications
between and through cells.

[39]
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Table 2. Cont.
Food Plant and Chitosan

Therapeutic Use

•
•
Chitosan

•
•

Chitosan

•
•
•

•
•

Chitosan

•

•
•

Used with non-SFP and was cross-linked with extract of
the non-SFP.
The highest dose levels of Punica granatum (Pg) extract,
rind extract and its spray dried biopolymeric
dispersions with casein (F1) or chitosan (F2) showed
notable hypoglycemic activity with 48, 52, and 40%
reduction in the mice glucose levels after 6 h,
respectively.
Used alone without linkage with the SFP.
The low molecular weight chitosan (LMWC)
LMWC-exendin-4 conjugate formed a nanoparticle
structure with a mean particle size of 101 ± 41 nm
through complexation between the positively charged
LMWC backbone and the negatively charged exendin-4
of individual conjugate molecules.
The biological activity of the LMWC-exendin-4
conjugate was evaluated in an INS-1cell line.
The absorbed exendin-4 demonstrated a significantly
enhanced hypoglycemic effect.
The LMWC-exendin-4 conjugate could be used as a
potential oral anti-diabetic agent for the treatment of
type 2 diabetes.
Used alone without cross-linkage with SFP.
The oral administration of 50 IU/kg insulin-loaded
nanoparticles to type 1 diabetic rats resulted in longer
period of anti-hyperglycemic effects up to 12 h and
relative pharmacological availability of 5.04%
comparing to the subcutaneous administration.
The oral anti-hyperglycemic effect was further
compared between type 1 and type 2 diabetic models
by the intraperitoneal glucose tolerance test, showing
that the effect lasted longer in the type 1 diabetic model.
The biopolymeric-based delivery.
Nano particulate system is a promising tool for the
therapy of Type 1 and Type 2 diabetic patients and
prevention of Type 1 diabetes.

Benefits/Nutritional Value

Reference

•
•

Chitosan enhances the healing of wounds.
Chitosan also eases both transport of medications
between and through cells.

[40]

•
•

Chitosan enhances the healing of wounds.
Chitosan also eases both transport of medications
between and through cells.

[41]

•
•

Chitosan enhances the healing of wounds.
Chitosan also eases both transport of medications
between and through cells.

[42]
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Table 2. Cont.
Food Plant and Chitosan

Therapeutic Use

•
•

•
Chitosan

•
•

•
•

•
Chitosan

•
•

Used without cross-linkage with SFP.
The in vitro and in vivo release of Ex4-C16 from
Decanoic acid-modified glycol chitosan (DA-GC)
hydrogels was intensely delayed compared to native
Ex4 possibly due to strong hydrophobic interactions.
Ex4-C16 in DA-GC hydrogels was found to be present
around the injection site up to 10 days after
subcutaneous administration, whereas Ex4 in DA-GC
hydrogels was not seen in the injection sites in
approximately 2 days in ICR mice.
The hypoglycemia induced by Ex4-C16 DA-GC
hydrogels was maintained for >7 days.
Ex4-C16 DA-GC hydrogels offer a potential delivery
system for the long-term effect treatment of Type
2 diabetes.
Used without cross-linkage with SFP.
Nanolayer cross-linkage and the development of
complexes permitted a superior loading capacity of
insulin (0.90%), as well as improved stability and 74%
reduced solubility at acid pH in vitro, compared to
non-cross-linked insulin.
The cross-linked insulin administered by oral gavage
reduced fasting blood glucose levels by up to 50% in a
sustained and dose-dependent manner and reduced
postprandial glycemia in streptozotocin-induced
diabetic mice without causing hypoglycemia.
Nanolayer cross-linkage decreased the likelihood of
rapid and erratic falls of blood glucose levels in animals.
A capable method to motivate the intestinal absorption
efficiency and release performance of the hormone,
possibly permitting an efficient and safe route for oral
insulin delivery of insulin in diabetes management.

Benefits/Nutritional Value

•

•

Reference

Chitosan enhances the healing of wounds. Chitosan
also eases both transport of medications between
and through cells.

[30]

Chitosan enhances the healing of wounds. Chitosan
also eases both transport of medications between
and through cells.

[31]
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Table 2. Cont.
Food Plant and Chitosan

Therapeutic Use

•
•

•
Chitosan

•

•
•

Chitosan

•

Used without cross-linkage with SFP.
The in vitro results indicated that all tested samples had
comparable rat α-glucosidase inhibitory and porcine
α-amylase inhibitory activity.
Based on these extrapolations, it was decided to further
examine the effect of all three samples at a dose of
0.1 g/kg, on decreasing postprandial blood glucose
levels in Sprague-Dawley (SD) rat model after sucrose
loading test.
In the animal trial, all tested samples had postprandial
blood glucose decrease effect, when compared to
control.
Used without cross-linkage with SFP.
Development of microparticles prepared by spray
drying of 2% alginate solution encapsulated by 0.1%
chitosan was characterized by good mucoadhesive
properties, high drug loading and longer period of
metformin hydrochloride release.
Designed microparticles decreased rat glucose blood
level, delayed absorption of metformin hydrochloride
and provided stable plasma drug concentration.

Benefits/Nutritional Value

•

•

Reference

Chitosan enhances the healing of wounds. Chitosan
also eases both transport of medications between
and through cells.

[32]

Chitosan enhances the healing of wounds. Chitosan
also eases both transport of medications between
and through cells.

[33]
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Chitosan acts by diffusing in the openings of tight junctions of epithelium, thereby
enhancing the healing of wounds. The selected food plants (MFP-2 unripe plantain, bitter
yam, and okra) acting in conjunction release plant insulin, which ultimately benefits
diabetics most especially in complicated states of unhealing wounds on the limbs (the arms
and legs). No scientific study so far has identified the combining or mixing effects of SFP
with chitosan for the management of T2D. Hence, the present systematic and meta-analysis
review aims to examine the relation of chitosan nanogel and MFP in T2D. MFP could
improve the blood glucose level in association with antidiabetic drugs [10].
2. Methods
The systematic review was conducted in agreement with the 2009 PRISMA statement [43]. The review procedure was recorded with PROSPERO in March 2019 (CRD
42019129124).
2.1. Search Strategy
We searched for journal papers indexed in PubMed, Medline, Scopus, as well as
Cochrane that were available from January 1990 to January 2021. The search was limited
to T2D alone, generally available in the English language using the search terms: “unripe
plantain, bitter yam, okra, chitosan with T2D.”
2.2. Study Selection, Inclusion as Well as Exclusion Criteria
The review included only studies that examined unripe plantain, bitter yam, okra,
and chitosan and their relation to type 2DM. Additionally, no human studies were included. Furthermore, we set a 28-year exploration boundary since therapeutic designs of
over 30 years-old may change significantly from natural plant therapy to nutraceutical
patterns [15]. Articles were searched and adjudicated. All searched articles were screened
by titles and abstracts so as to retrieve useful journals deemed to be eligible. We revised
journal paper completely according to standards set. Forms of differences were resolved by
consensus-oriented discussion; where there was no resolution, a third party was consulted.
2.3. Information Extraction
Information on features involved in the revisions was taken out individually with
the help of two critics. The first critic extracted textual data and the other graphical data
(Figures). Authors were contacted where necessary through their e-mails or phone numbers
published in their articles for additional or missing data. The data extracted were related
to the number of experimental groups in the study design (i.e., the group which was
induced and the one receiving intervention). Both species and sex of animal related to
the characteristics of the animal model were extracted from the data. The intervention of
interest, dosage, timing of dosage, and effectiveness of dosage on the animal’s data was
extracted [44]. The primary outcome data support a reduction in hyperglycemia and the
unit of measurement was milligrams per deciliter (mg/dL) or millimole per litre (mmol/L).
All extracted data were in a continuous data pattern.
2.4. Assessing the Risk Bias
The method of assessing bias risk or assessing quality involved individually assessing
risk associated with bias as well as studies included, which were evaluated by two external
reviewers, one on text data and the other on graphical data (Figures). Disagreement
was resolved by consensus-oriented discussions and where resolution was not reached,
a third party was consulted. Studies were evaluated with the Systematic Review Centre
for Laboratory Animal Experimentation (SYRCLE) tool for assessing bias risk in animal
studies [37]. We regarded individual areas to be at ‘low risk’, ‘unclear risk’ or ‘high risk’ of
bias. We generally categorized the bias risk to be ‘low’ when the answer to the signaling
questions for that domain was “Yes”, ‘high’ when the answer to the signaling questions was
“No”, or as ‘unclear’ when there was insufficient information about that domain (Table 3).
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Table 3. Use of SYRCLE’s tool for assessing risk of bias.
Item

1

Type of Bias

Domain

Description of Domain

Review Author’s
Judgement

Selection bias

Sequence
generation

There is direct evidence that cases and controls were
similar, recruited within the same time frame, and
controls are described as having no history of the
outcome.

Yes *

Yes

2

Selection bias

Baseline
characteristics

There is direct evidence that appropriate adjustments
were made for covariates and confounders in the
final analyses through the use of statistical models to
reduce research-specific bias including
standardization, matching of cases and controls,
adjustment in multivariate model, stratification,
propensity scoring, or other methods were
appropriately justified.

3

Selection bias

Allocation
concealment

There is insufficient information on concealment in
the allocation of the animals into groups and
subgroups.

No *

4

Performance bias

Random
housing

There is direct evidence that the housing of animals
was not random as they were kept in cages in the
animal house.

No

5

Performance bias

Blinding

There is direct evidence that caregivers and
researchers were not blinded or information was not
provided.

No

6

Detection bias

Random
outcome
assessment

There is indirect evidence that it was possible for
outcome assessors to infer the exposure level prior to
reporting outcomes.

No

Yes

7

Detection bias

Blinding

Investigators also served as outcome assessors. There
is direct evidence that exposure was consistently
assessed using well-established methods that directly
measure exposure like the blood glucose levels.

8

Attrition bias

Incomplete
outcome data

There is no information provided on subject removal
or exclusion from the study.

No *

9

Reporting bias

Selective
outcome
reporting

There is direct evidence that all of the study’s criteria
were measured in the protocol, such as methods,
abstract and introduction have been reported.

Yes *

10

Others

Other sources of
bias

There is direct evidence that the other bias like
“Units” was reported. Appropriate units such
as mg/dl and mmol/L were assigned.

Yes *

* Items in agreement with the items in the Cochrane Risk of Bias tool, Yes = Low Risk of Bias, No = High Risk of Bias.

2.5. Strategy for Information Investigation
Effects regarding outcome remained stated with statistical difference at 95%CI, considered from both end standards or modifying the starting point. Through studies, effects on
blood glucose level remained constantly obtainable as milligram per deciliter or millimole
per liter (mg/dL or mmol/L).

#

1
2
3
4
5
6
7
8
9
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CI
CI Upper
Lower
Weight Q
PQ
I2
T2
Limit
Study Name/Subgroup Effect CI Lower
CI Upper
Limit
PQ
I2
T2
1
Shodehinde et al., 2015 [3]
13.02
10.98
15.06 Weight
21.82%Q
Name2 Eleazu and Okafor; 2015Size
Limit
Limit
[5]
3.17
2.56
3.78
25.94%
3
Eleazu et al., 2013 [36]
2.06
1.51
2.60
26.03%
4
Huang
al., 2017
[15] 13.02 10.98
0.86
0.4715.061.25
26.22%
Shodehinde
etetal.,
2015
21.82%
5
AA
4.42
−0.82 9.66
17.78% 162.77 0.000
98.16% 5.01
Eleazu
Okafor;
2.56
25.94%
6 and
Lopes
et al., 20172015
[42] 3.17
2.18
1.623.78 2.74
49.87%
7
and Samy, 2014 [40]
4.66
4.17
50.13%
Eleazu
etRaafat
al., 2013
2.06 1.51
2.60 5.15
26.03%
8
BB
3.43
0.99
5.86
82.22% 43.54
0.000
97.70% 3.00
9 etCombined
Effect Size 0.86
3.60
1.031.25 6.17
258.29 0.000
98.06% 4.07
Huang
al., 2017
0.47
26.22%
N.B, AA = Diabetic intervention group, BB = Negative diabetic control group.
#

Study Name/Subgroup Name

AA
Lopes et al., 2017
Raafat and Samy, 2014
BB
Combined Effect Size

4.42
2.18
4.66
3.43
3.60

Effect
Size

−0.82
1.62
4.17
0.99
1.03

9.66
2.74
5.15
5.86
6.17

17.78%
49.87%
50.13%
82.22%

T

T

PI
PI Upper
Lower
PI
Limit
Limit PI Lower

Limit

2.24 −6.65

15.50

1.73 −23.65
2.02 1.03

30.50
6.17

Upper
Limit

162.77 0.000 98.16% 5.01

2.24

−6.65

15.50

43.54 0.000 97.70% 3.00
258.29 0.000 98.06% 4.07

1.73
2.02

−23.65
1.03

30.50
6.17
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Table 5. Publication bias analysis confirming effect sizes and I2 values.
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N.B, AA = Diabetic
intervention group, BB = Negative diabetic
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Figure 2. Funnel plot showing random effect meta-analysis of mean difference in decrease of blood

Figure
2. Funnel
plot showing
random effect
meta-analysis
of mean difference in decrease of blood
glucose level
(mg/dL) based
on diabetic intervention
or negative
diabetic control.
glucose level (mg/dL) based on diabetic intervention or negative diabetic control.

Hooijmans [37] reported that calculating the instant mark among separate investigations was not a good practice using the SYRCLE’s tool because an instant mark will
involve allocating “loads” particular to known areas to tool, which will be problematic
when justifying loads allocated. Moreover, loads could vary for every result and for
every analysis.
2.6. Patients as Well as General Participation
While the investigation limited the enrollment of human participants, the evaluation
was entirely focused on animals only. However, due to the nature of the research question,
its result was extrapolated to patients and the public.
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3. Outcomes (Results)
3.1. Explored Outcomes

Screening

Identification

The exploration of four automated records (Medline, Scopus, PubMed, and Cochrane)
identified 405,919 collections through 454 journal papers left over once excluding replicas.
Out of this number, 417 journal papers were disqualified as the titles and abstract were
lacking our criteria, and those journal investigation reports were not of the standards set.
Out of 37 selected journal papers, 19 investigational journal report papers were dropped
due to not been a precise case investigation, in vivo as well as in vitro animal study, not
SFP cross-linked with chitosan, not having modulator blockers or enzyme inhibitors, and
Nutrients 2022, 14, x FOR PEER
of 34
notREVIEW
insulin stimulated or secreted on account of SFP as outcome. Thus,16 18
studies were
identified as eligible for inclusion in the review (Figure 3) [43].

Records identified through UNIC database
searching (Medline and Scopus)
Jan
1990 – Jan 2021
(n = 384,065)

Additional records identified through other
database sources (PubMed and Cochrane)
Jan 1990 – Jan 2021
(n = 21, 854)

Records after duplicates removed
(n = 454)

Eligibility

Records Identified after screening titles
and abstracts
(n = 454)

Full-text articles assessed for
eligibility
(n = 37)

Studies included in analysis
(n =18)

Included

Records excluded: Conference
papers, books and reviews
papers, where intervention was
not Type 2 diabetes, animal
study and use of Specified Food
Plants (SFP)
(n = 417)

Studies included in metaanalysis
(n = 6)

Full-text articles excluded, with
reasons: - No Insulin stimulated
and secreted on account of SFP
as outcome. – No modulators
blockers or enzyme inhibitors of
insulin. – No SFP cross-linked
with chitosan. – No in vivo or in
vitro animal study. – No case
controlled study.
(n = 19)
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Table 6. General characteristics of included studies Baseline characteristics of rats or cell lines.

Stydy/Country

N,
Characteristics [No. of
Cells-In Vitro or No of
Rats-In Vivo, Weight (Wt.)
of Rats (Rts) No of Group
(Grp)]

Shodehinde, S.A. et al.
Life Sci. 2015 [3]/
Nigeria

42 male rats (in vivo),
Wt = 200 g,
Grp-7

Study Duration

FP or Material and Family/BM/T

•
•

14 days

Musa parasidiaca
(Musaaceae)/Carotenoids,
Polyphenols, Potassium and
Vitamin C/NT

Reagent for Induction of
Diabetes/SL(Average) Post
Induction

Description of the Study

Streptozotocin/≥
250 mg/dl

The effect of the diets on the blood
glucose level, pancreatic α-amylase,
intestinal and α-glucosidase content of
the unripe plantain products was
determined.

•
Famakin, O. et al. J.
Food Sci. Technol.
2016 [23]/Nigeria

•

60 Wistar albino,
Wt = 150 g Grp-6

•

28 days

Musa parasidiaca
(Musaaceae)/
Carotenoids, Polyphenols,
potassium and Vitamin C/NT

•

Alloxan
monohydrate/≥
250 mg/dl

•

•
Ajiboye, B.O. et al.,
Food Sci Nutr.
2018 [35]
Nigeria

•
48 Albino rat,
Wt = 150 ± 20 gGrp- 4

•

28 days

Musa parasidiaca
(Musaaceae)/Carotenoids,
Polyphenols, potassium and
Vitamin C/NT

•

Alloxan
monohydrate/≥
250 mg/dl

•

•

Eleazu, C.O.; Okafor,
P. Interv. Med. Appl.
Sci. 2015 [5]
Nigeria

48 male albino,
Wt = 243 g,
Grp-3

•
•

28 days

Musa parasidiaca
(Musaaceae)/Carotenoids,
Polyphenols, potassium and
Vitamin C/NT

•

Streptozotocin/≥
200 mg/dl

Four of the Grps were fed with
prepared food samples (PSC-1,
PSC-2, PSC-3 and 100 %
plantain).
The remaining Grps were treated
with Cerolina (a control sample)
and metformin hydrochloride
(an antidiabetic drug) and
commercial animal feed.
Grp 3 diabetic rats fed with D.
rotundata-based diet and
administered metformin orally
(14. 2 mg/kg) and Grp 4 diabetic
rats fed with unripe M.
paradisiaca-based diet.
Grp 1 non-diabetic rats fed with
D. rotundata flour-based diet.
Grp 2 diabetic control rats fed
with D. rotundata-based diet.

Grp 3 diabetic rats fed with
unripe plantain pellets (81%)
•
Grp 1 normal rats fed with
standard rat pellets
(non-diabetic control)
•
Grp 2 diabetic control rats fed
with standard rat pellets
Blood test was monitored for Rts
nourished with Musa parasidiaca
related by non-diabetic rats.

Outcome Measures with
the Use of FP

•

Blood glucose level
from 350 to
200 mM/L (p < 0.05),
α-amylose and
α-glucosidase
(p < 0.05).

Blood glucose change
from 355 ± 43 to
103 ± 14 mg/dl
(p < 0.05). Weight change
noted

Blood glucose change
from 350 to 100 mg/dl
(p < 0.05). Physique
heaviness as well as
hyperglycemia was
measured

•

Hyperglycemia as
well as stopping
blood test for
diagnosing or
monitoring
hyperglycemic
problem. Ratio of %
hyperglycemia 2.05
to −159.52%
(p < 0.05).
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Table 6. Cont.

Stydy/Country

N,
Characteristics [No. of
Cells-In Vitro or No of
Rats-In Vivo, Weight (Wt.)
of Rats (Rts) No of Group
(Grp)]

Study Duration

FP or Material and Family/BM/T

Reagent for Induction of
Diabetes/SL(Average) Post
Induction

Description of the Study

Outcome Measures with
the Use of FP

•

Eleazu, C.O.; et al. J.
Diabetes Res.
2013 [36]
Nigeria

•
40 male albino,
Wt= 288.74 g

•

21 days

Colocasia esculenta and
Musa parasidiaca
(Musaaceae)/Carotenoids,
Polyphenols, potassium and
Vitamin C/NT

•

Streptozotocin/≥
200 mg/dl

Grp 4 diabetic rats administered
cocoyam combined feed;
•
Grp 5 diabetic rats administered
unripe plantain combined feed.
Grp1 normal rats administered
standard rat pellets (non- diabetic
control);

Hyperglycemia as well as
heaviness change
Decreased of SL by
38.13% (p < 0.05)

•

•

•

•
•
Sukanya, C. et al.
Glyset (Miglitol). Bull
Environ Contam
Toxicol. 2016 [27].
Nigeria

•
35 Wistar albino,
Wt = 150 g,
Grp-5.

•

28 days

Musa parasidiaca
(Musaaceae); Glycine max
(Fabaceae/Carotenoids,
Polyphenols, potassium and
Vitamin C-/NT-

•

Alloxan monohydrate,
≥
250 mg/dl,

Grp 2 diabetic control rats
administered 55 mg/kg body
weight STZ;
Grp 3 diabetic control rats
administered 70 mg/kg body
weight STZ
Three groups were fed with the
experimental diets (PSR1, PSR2,
and PSR3),
Another group was treated with
metformin hydrochloride
(antidiabetic drug) and saline
solution and fed with
commercially available animal
feeds, and the last group was fed
with Cerolina (a control flour
sample commonly
recommended for diabetic
patient)

•

Musa parasidiaca
decreased Wt and
growth by 29.52%

Lowered blood
glucosefrom 129.92
± 52.80 to 55.00 ±
12.25 mg/dl
(p < 0.05)
Stabilizing the lipid
profiles
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Table 6. Cont.

Stydy/Country

N,
Characteristics [No. of
Cells-In Vitro or No of
Rats-In Vivo, Weight (Wt.)
of Rats (Rts) No of Group
(Grp)]

Study Duration

FP or Material and Family/BM/T

Reagent for Induction of
Diabetes/SL(Average) Post
Induction

Description of the Study

•
•
Iroaganachi, M.; et al.,
Biochem. J. 2015 [4].
Nigeria

30 male albino,
Wt = 232.91 g,
Grp-4

•

28 days

Musa parasidiaca
(Musaaceae); Zingber
officinale (Zingiberaceae)/Carotenoids,
Polyphenols, potassium and
Vitamin C/NT

•

Streptozotocin,
≥200 mg/dl

•

•
Hooijmans, C.R.;et al.,
ILAR J. (2014), [37].
Nimenibo-Uadia, R.
et al., Pa. J. Appl. SCI.
Environ Manag.
2017 [22].
Republic of Korea

•

50 male
Sprague-Dawley (SD),

•

•

31 days

Wt = 250 g,
Grp-5

Bitter yam (Dioscorea
batatas)/
Polyphenols and Alkaloids,
Tannins and anthraquinones are
absent/None T.

•

Streptozotocin,
350 mg/dl

Suspended crude yam powder-treated
diabetic; water extract of yam-treated
diabetic and allantoin-treated diabetic
group normal control, STZ-induced
diabetic control

•

•

Nguekouo, P.T.;et al.,
J. Food Biochem.
2018 [24].
Thule, Umpierrez.
Curr Diab Rep, 2014,
14 [28].
Cameroon

•
60 wistar albino,
Wt = 200 g,
Grp-6

•

28 days

Okra-Abelmoschus
esculentus (Mallow)
Malvaceae/
Polysaccharides and major
flavonoids, isoquercitrin and
quercetin 3-O-gentiobioside,
Different levels of Asenic is
reported to absorbed into the
plant/None T.

•

Streptozotocin,
≥200 mg/dl

Grp 3. Diabetic rats fed unripe
plantain combined feeds
(810 g/kg) Grp 4 diabetic rats
fed unripe plantain and ginger
combined feeds (710: 100 g/kg)
Grp 1 normal rats fed with
standard rat pellets
(non-diabetic control). Grp 2
diabetic control rats which also
received standard pellets
I

•

Grps 1 and 2 served as untreated
fruits and boiled fruits (200
mg/kg)-treated diabetic rats,
respectively. Grps 3 and 4 served
as untreated seeds and roasted
seeds (200 mg/kg)-treated
diabetic rats, respectively.
Grp 6 served as diabetic control
(positive) received distilled
water (4 ml/kg). The animals
fed with normal diet were used
as normal control (negative) Grp
and received distilled water (4
mL/kg) and Grp 5 served as
standard drug, metformin (300
mg/kg)-treated diabetic rats

Outcome Measures with
the Use of FP

•

•

•

Blood glucose
change from
252.25 ± 40.32 to
97.20 ± 11.10 mg/dl
(p < 0.05). Weigh
change noted.
45.36 % reduction of
heaviness

Blood glucose
change from
494 ± 81 to
128 ± 20 mg/dl
(p < 0.05). Blood
lipid change noted.

Blood glucose change
from 333 ± 20 to
119 ± 18 mg/dl (p < 0.05)
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Table 6. Cont.

Stydy/Country

N,
Characteristics [No. of
Cells-In Vitro or No of
Rats-In Vivo, Weight (Wt.)
of Rats (Rts) No of Group
(Grp)]

Study Duration

FP or Material and Family/BM/T

Reagent for Induction of
Diabetes/SL(Average) Post
Induction

Description of the Study

•

•
•

Huang, C.; et al.,
PLoS One. 2017 [15].
South Africa

Different levels of
Asenic is reported to
absorbed into the
plant
32 male Sprague-Dawley,
Wt = 250 ± 20 g Grp10.

•
•

84 days

Okra (Abelmoschus
esculentus)/Polysaccharides
and major flavonoids,
isoquercitrin and quercetin
3-O-gentiobioside/NT.

•

Streptozotocin, ≥
250 mg/dl

•

Diabetes with 0.23 mg/kg F1,
diabetes with 0.45 mg/kg F1,
diabetes with 0.23 mg/kg F2,
diabetes with 0.45 mg/kg F2,
diabetes with 0.23 mg/kg FR,
diabetes with 0.45 mg/kg F3.
Control (normal diet), C1-C3
(normal diet with 0.45 mg/kg F1,
F2, or FR added), HFD with STZ
injection; diabetes model Serum
glucose quickly increased and
insulin resistance was noted in
the diabetic rats (glucose:
360–500 mg/dl, HOMA-IR
9.8–13.8).
F2, rich in polysaccharides and
carbohydrates, was most
effective in reducing
hyperglycemia and insulin
resistance (glucose: 200 mg/dl;
HOMA-IR: 5.3)

Outcome Measures with
the Use of FP

Blood Glucose change
from 500 to 120 mg/dl

•

Insulin resistance
noted.
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Table 6. Cont.

Stydy/Country

N,
Characteristics [No. of
Cells-In Vitro or No of
Rats-In Vivo, Weight (Wt.)
of Rats (Rts) No of Group
(Grp)]

Study Duration

FP or Material and Family/BM/T

Reagent for Induction of
Diabetes/SL(Average) Post
Induction

Description of the Study

•

•

•

Lee, J.; et al., J.
Control Release.
2012 [39].
Republic of Korea

48 male db/db mice,
Wt unspecified,
Grp-8,

•

3 days

Chitosan (Poliglusan,
Deacetylchitin;
Poly-D)glycosamines),
Chitopharm/
Natural biopolymer; obtained via
deacetylation process of
chitin/NT

•
Insufflation
Administration, Blood
glucose confirmed by
glucometer at specified
time-range

•

•

Pulmonary hypoglycemic
efficacies, 50 µL of Ex4 or
Ex4-C16 DOCA-GC nanogels
(320 µg/mL as Ex4 or Ex4-C16;
100 nmol/kg mouse, and 20
mg/mL as DOCA-GC) were
administered by insufflation to
male db/db mice
A portion (50 µL) of Ex4 or
Ex4-C16 solution (100 nmol/kg)
was administered as positive
controls, and Ex4 non-loaded
DOCA-GC nanogels were also
administered as a negative
control.
The lung deposition of
DOCA-GC nanogels was
monitored using an infrared
imaging system, and the
hypoglycemia caused by
Ex4-C16-loaded DOCA-GC
nanogels was evaluated after
pulmonary administration in
T2D db/db mice. the Ex4-C16
release from DOCA-GC
nanogels was seriously delayed
vs. Ex4.
DOCA-GC nanogels were
deposited quickly after
pulmonary administration and
stayed in the lungs for
approximately72 h. Also, the
hypoglycemic period of inhaled
Ex4-C16 nanogels was much
better than that of Ex4 nanogels
in db/db mice.

Outcome Measures with
the Use of FP

Blood Glucose change
from 150 to 57 mg/dl
(p < 0.05)

•

Hypoglycemia and
drug sustained
release time.
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Table 6. Cont.

Stydy/Country

N,
Characteristics [No. of
Cells-In Vitro or No of
Rats-In Vivo, Weight (Wt.)
of Rats (Rts) No of Group
(Grp)]

Study Duration

FP or Material and Family/BM/T

Reagent for Induction of
Diabetes/SL(Average) Post
Induction

Description of the Study

•

•
Raafat, K.; et al., Evid.
Based Compl. Alt.
2014 [40].
Lebanon

112 Swiss webster mice,
Wt = 280 gGrp-16.

•

8 days

Pomegranate (Punica
granatum L.) Lythraceae
(Punicaceae), Natural
biopolymer; obtained via
deacetylation process of
chitin/NT

•

Alloxan monohydrate,
200 mg/dl

•

Grps 3, 4, and 5 was given the
Pg extract dissolved in vehicle at
doses of 25, 50, and 100 mg/kg,
respectively. (iv) Grps 6, 7, and 8
was given F1, suspended in
vehicle at doses equal to 25, 50,
and 100 mg Pg extract/kg,
respectively. (v) Grp 8 was given
placebo F1 suspended in vehicle
(200 mg/kg). (vi) Grps 9, 10, and
12 was given F2, suspended in
vehicle at doses equal to 25, 50,
and 100 mg Pg extract/kg,
respectively. (vii) Grp 13 was
given placebo F2 suspended in
vehicle (200 mg/kg). (viii) Grps
15, 16, and 17 was given gallic
acid (GA) dissolved in DMSO, at
doses of 3,6, and 12 mg/kg to
the animals, respectively.
Grp 1 was given only vehicle
(0.9 % sterile saline) and served
as control. (ii) Grp 2 was given
glibeclimide dissolved in DMSO
as reference drug (5 mg/kg).

Outcome Measures with
the Use of FP

•

Blood glucose
change from
210.15 ± 7.30 to
138.89 ± 1.45 mg/dl
(p < 0.05) and
DNnoted.
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Table 6. Cont.

Stydy/Country

N,
Characteristics [No. of
Cells-In Vitro or No of
Rats-In Vivo, Weight (Wt.)
of Rats (Rts) No of Group
(Grp)]

Study Duration

FP or Material and Family/BM/T

Reagent for Induction of
Diabetes/SL(Average) Post
Induction

Description of the Study

•

•
Raafat, K.; et al., Evid.
Based Compl. Alt.
2014 [40].
Lebanon

112 Swiss, webster mice,
Wt= 280 g,
Grp-16

•

8 days

Pomegranate (Punica
granatum L.) Lythraceae
(Punicaceae)/Natural
biopolymer; obtained via
deacetylation process of
chitin/NT

Alloxan monohydrate,
200 mg/dl

•

•

(iii) Grps 4, 5, and 6 was given
Pg extract dissolved in vehicle at
doses of 25, 50, and 100 mg/kg,
respectively. (iv) Grps 7, 8, and 9
was given F1 suspended in
vehicle at doses equal to 25, 50,
and 100 mg Pg extract/kg,
respectively. (v) Grp 10 was give
placebo F1 suspended in vehicle
200 mg/kg. (vi) Grps 11, 12, and
13 was given Pg F2 suspended in
vehicle at doses equalt to 25, 50,
and 100 mg Pg extract/kg,
respectively. (vii) Grp 14 was
given placebo F2 suspended in
vehicle 200 mg/kg. (viii) Grps
15, 16, and 17 was given GA,
dissolved in DMSO, at doses of
3,6, and 12 mg/kg, respectively.
Grp 2 was given only vehicle
(0.9% sterile saline) and served
as diabetic control. (ii) Grp 3 was
given glibeclimide dissolved in
DMSO as reference drug (5
mg/kg, IP).
Subacute (8 days) effect of
various doses of Pg, F1, and F2
and the active compounds.

Outcome Measures with
the Use of FP

•

Blood glucose
change from 214.21
± 9.70 to 181.56 ±
2.02 mg/dl (p < 0.05)
and DN noted.
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Table 6. Cont.

Stydy/Country

N,
Characteristics [No. of
Cells-In Vitro or No of
Rats-In Vivo, Weight (Wt.)
of Rats (Rts) No of Group
(Grp)]

Study Duration

FP or Material and Family/BM/T

Reagent for Induction of
Diabetes/SL(Average) Post
Induction

Description of the Study

•

Ahn, S.; et al., J.
Control Release,
2013 [41].
Republic of Korea

Mouse,
Pancreatic
Cell lines
(INS-1),
18 male db/db mice, Wt
unspecified
Grp-3)

•

•

3 days

Chitosan (poliglusan,
Deacetylchitin;
Poly-(D)glycosamines),
Chitopharm/
Natural biopolymer; obtained via
deacetylation process of
chitin/NT

•

Formulation and
glucose administered,
intraperitoneal
glucose tolerance test
(IPGTT

Exendin-4-cys, and
LMWC-exendin-4 conjugate.PBS
control (PBS-EDTA buffer pH =
7.4). The LMWC-exendin-4
conjugate formed a nanoparticle
structure with a mean particle
size of 101 ± 41 nm through
complexation between the
positively charged LMWC
backbone and the negatively
charged exendin-4 of individual
conjugate molecules. The
biological activity of the
LMWC-exendin-4 conjugate was
estimated in an INS-1 cell line.
The LMWC-exendin-4 conjugate
stimulated insulin secretion in a
dose dependent manner as
similar as that of natural
exendin-4.

Outcome Measures with
the Use of FP

•

Insulin
concentration and
dose release time.
Blood glucose
change from
211.93 ± 4.50 to
142.44 ± 2.80 mg/dl
(p < 0.05)

•

Sustained
drug-release time.
Blood Glucose
change from
234.21 to
164.56 mg/dl
(p < 0.05)

•

•

Lopes, M.;et al.; Eur. J.
Pharm. Biopharma.
2017 [42].
Portugal

36 male wistar,
Wt= 350 g,
Grp-3

•

10 days

Chitosan can also be
referred at as poliglusan,
Deacetylchitin;
Poly-(D)glycosamines,
Chitopharm,
Natural biopolymer; obtained via
deacetylation process of
chitin/Non-toxic,

Streptozotocin, ≥14 mM
Subcutaneous (S.C.)

•

Administration

50 IU/kg insulin-loaded NP, (ii)
empty NP.
(iii) without administration, compared
with control Wistar rats (n = 10).
The oral administration of 50 IU/kg
insulin-loaded nanoparticles to Type 1
diabetic rats resulted in extended
period of antihyperglycemic effects up
to 12 h and relative pharmacological
availability of 5.04% comparing to the
subcutaneous administration.
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Table 6. Cont.

Stydy/Country

N,
Characteristics [No. of
Cells-In Vitro or No of
Rats-In Vivo, Weight (Wt.)
of Rats (Rts) No of Group
(Grp)]

Study Duration

FP or Material and Family/BM/T

Reagent for Induction of
Diabetes/SL(Average) Post
Induction

Description of the Study

Outcome Measures with
the Use of FP

•
•

•

Lopes, M.;et al.; Eur. J.
Pharm. Biopharma.
2017 [42].
Portugal

•
40 male wistar,
Wt = 350 gGrp-5

•

10 days

Chitosan can also be
referred at as poliglusan,
Deacetylchitin;
Poly-(D)glycosamines,
Chitopharm,
Natural biopolymer; obtained via
deacetylation process of chitin.

•

Streptozotocin, ≥14
mM, intraperitoneal
glucose tolerance test
(IPGTT).

50 IU/kg insulin-loaded NP,
(ii) 100 IU/kg insulin-loaded NP
or (iii) non-encapsulated insulin,
all orally delivered by gavage.
•
(iv) subcutaneous (s.c.)
non-encapsulated insulin.
The oral antihyperglycemic effect was
further compared between T1D T2D
by the intraperitoneal glucose
tolerance test, revealing that the effect
lasted longer in the T1D.

Sustained drug-release
time
10 days

•

•
Lee, C; et al., Acta
Biomater. 2014 [30].
Republic of Korea

Murine, melanoma B16F10
cell lines (20,000 cells
seeded),
18 male db/db mice,
Grp-3 Wt not specified

•

5 days

Chitosan (poliglusan,
Deacetylchitin;
Poly-(D)glycosamines),
Chitopharm/Natural
biopolymer; obtained via
deacetylation process of
chitin/NT

•
Subcutaneous (S.C.)
Administration.

Hypoglycemic efficacies, Ex4 or
Ex4-C16 DA-GC hydrogels (100
u.g as Ex4) were administered
by single s.c. injection using a
21-gauge needle into male db/db
mice
Blank DA-GC hydrogels were also
administered as controls.
•
The in vitro and in vivo release
of Ex4-C16 from DA-GC
hydrogels was effectively
delayed compared with natural
Ex4 probably due to strong
hydrophobic interactions.
Specifically, Ex4-C16 in DA-GC
hydrogels was found to be
present around the injection site
up to 10 days after subcutaneous
administration, whereas Ex4 in
DA-GC hydrogels was cleared
from injection sites in
approximately2 days in ICR
mice.

•

Sustained drug
release-time;
hypoglycemia effect.
Blood Glucose
change from 291.83
to 144.44 mg/dl
(p < 0.05)
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Table 6. Cont.

Stydy/Country

N,
Characteristics [No. of
Cells-In Vitro or No of
Rats-In Vivo, Weight (Wt.)
of Rats (Rts) No of Group
(Grp)]

Study Duration

FP or Material and Family/BM/T

Reagent for Induction of
Diabetes/SL(Average) Post
Induction

Description of the Study

•

•

Song, L.; et al., Int. J.
Nanomedicine.
2014 [31].
United Kindom

30 male mice,
Wt= 30 g
Grp-5

•

14 days

Chitosan can also be
referred at as poliglusan,
Deacetylchitin;
Poly-(D)glycosamines,
Chitopharm,
Natural biopolymer; obtained via
deacetylation process of
chitin/NT

•

Streptozotocin, ≥≥20
mmol/L

•

•
•

Jo, S.; et al., Int. J. Mol.
Sci. 2013 [32].
Republic of Korea

30 male Sprague Dawley
(SD),
Wt= 200 g,
Grp-6

•

14 days

Chitosan (poliglusan,
Deacetylchitin;
Poly-(D)glycosamines),
Chitopharm/
Natural biopolymer; obtained via
deacetylation process of
chitin/NT,

•

Sucrose and inhibitors
administered,
Diabetes confirmed by
glucose oxidase
method

•
•

Outcome Measures with
the Use of FP

The resulting preparations were
administered separately to the
diabetic mice with doses of 30
and 60 units/kg (fasting) and 60
and 120 units/kg (fed):
multilayer-coated capsule
containing insulin
microparticles,
multilayer-coated capsule
containing insulin-chitosan
particles (20 IU/kg).
The following preparations were
administered separately to the
diabetic mice with doses of 30
and 60 units/kg (fasting) and 60
and 120 units/kg (fed):
insulin-alone microparticles,
insulin-chitosan microparticles,
and ip injection of the free-form
insulin solution (20 IU/kg).

Blood glucose change
from 60 to 20 mMolL
(p < 0.05) and sustained
drug release dosage.

Inhibitors (GO2KA1, GO2KA2,
GO2KA3) administered.
No inhibitors and Acarbose
administered.
Entirely verified models needed
up surges in hyperglycemia
decreasing outcome, once
related toward regulating,
conversely the supplementation
needed highest outcome.

Blood Glucose change
From193 to 152 mg/dl
(p < 0.5), α-amylase and
α-glucosidase inhibition
at sustained time.
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Table 6. Cont.

Stydy/Country

N,
Characteristics [No. of
Cells-In Vitro or No of
Rats-In Vivo, Weight (Wt.)
of Rats (Rts) No of Group
(Grp)]

Study Duration

FP or Material and Family/BM/T

•
Szekalska, M.; et al.,
2017 [33].
Poland

30 male Sprague Dawley
(SD),
Wt = 250 ± 20 g Grp-5.

•

28 days

•

Chitosan can also be
referred at as poliglusan,
Deacetylchitin;
Poly-(D)glycosamines,
Chitopharm,
Natural biopolymer;
obtained via deacetylation
process of chitin/NT

Reagent for Induction of
Diabetes/SL(Average) Post
Induction

Description of the Study

Outcome Measures with
the Use of FP

•

•

Streptozotocin, ≥
250 mg/dl

Non cross-linked microparticles
preparation C, cross-linked
microparticles preparation
CH1M and commercially
available tablet with metformin
hydrochloride (MF)
Rats treated with carboxymethyl
cellulose sodium salt (Control),
microparticles placebo (ALG).

•
•

Blood glucose
change from 305 to
262 mg/dl (p < 0.05)
and drug release
time.

Grp—Group; Wt—Weight; Rts—Rats; FP—Foof Plant; BM—Bioactive Molecules; T—Toxicity; STZ—Streptozotocin; SL—Sugar level; NT—Non-Toxic; DN—Diabetic Neuropathy.

Nutrients 2022, 14, 4710

27 of 33

The invesstigations consisted of seven involving unripe plantain [2,5,11,26,35,36,47],
one involving bitter yam [25], two involving okra [15,24], and eight involving
chitosan [7,10,29–33,48] respectively. Almost all the included studies were in vivo casecontrolled studies which were induced with diabetes using streptozotocin (STZ) and four
others with alloxan monohydrate [2,5,30,35]. The major intervention from the studies was
Type 2 diabetes with few other interventions in some studies, such as enzyme inhibition,
weight change, lipid decrease/insulin resistance, sustained release time, and neuropathy.
In all these interventions, SFP were used either in combination with other (NSFP) or used
alone without cross-linking them with chitosan. As such, chitosan was used alone to encapsulate either insulin or other active compounds to aid their release over a sustained time.
The main outcome measure in all the included studies was a decrease of blood glucose
level in the animals.
3.3. The Bias Risk across Investigations
Complete information of the risk bias investigation of animal studies is presented
in Table 7.
Table 7. Risk of bias assessment in case-controlled animal studies.

Others

Overall
Review
Author’s
Judgement

Reference

Low risk

Low risk

Unclear *

[3]

Low risk

Low risk

Unclear *

[23]

High risk

Low risk

Low risk

Unclear *

[35]

Low risk

High risk

Low risk

Low risk

Unclear *

[5]

High risk

Low risk

High risk

Low risk

Low risk

Unclear *

[36]

High risk

Low risk

High risk

Low risk

Low risk

Unclear *

[2]

High risk

High risk

Low risk

High risk

Low risk

Low risk

Unclear *

[4]

High risk

High risk

High risk

Low risk

High risk

Low risk

Low risk

Unclear *

[37]

High risk

High risk

High risk

High risk

Low risk

High risk

Low risk

Low risk

Unclear *

[24]

Low risk

High risk

High risk

High risk

High risk

Low risk

High risk

Low risk

Low risk

Unclear *

[15]

Low risk

High risk

High risk

High risk

High risk

Low risk

High risk

Low risk

Low risk

Unclear *

[39]

Low risk

Low risk

High risk

High risk

High risk

High risk

Low risk

High risk

Low risk

Low risk

Unclear *

[40]

Low risk

Low risk

High risk

High risk

High risk

High risk

Low risk

High risk

Low risk

Low risk

Unclear *

[41]

Low risk

Low risk

High risk

High risk

High risk

High risk

Low risk

High risk

Low risk

Low risk

Unclear *

Low risk

Low risk

High risk

High risk

High risk

High risk

Low risk

High risk

Low risk

Low risk

Unclear *

Low risk

Low risk

High risk

High risk

High risk

High risk

Low risk

High risk

Low risk

Low risk

Unclear *

[31]

Low risk

Low risk

High risk

High risk

High risk

High risk

Low risk

High risk

Low risk

Low risk

Unclear *

[32]

Low risk

Low risk

High risk

High risk

High risk

High risk

Low risk

High risk

Low risk

Low risk

Unclear *

[33]

Selection
Bias

Selection
Bias

Selection
Bias

Performance Performance Detection
Bias
Bias
Bias

Detection
Bias

Attrition
Bias

Reporting
Bias

Low risk

Low risk

High risk

High risk

High risk

High risk

Low risk

High risk

Low risk

Low risk

High risk

High risk

High risk

High risk

Low risk

High risk

Low risk

Low risk

High risk

High risk

High risk

High risk

Low risk

Low risk

Low risk

High risk

High risk

High risk

High risk

Low risk

Low risk

High risk

High risk

High risk

Low risk

Low risk

High risk

High risk

High risk

Low risk

Low risk

High risk

High risk

Low risk

Low risk

High risk

Low risk

Low risk

Low risk
Low risk

[30,42]

Unclear * = Insufficient information; NB: Refer to Table 3, for better understanding of Table 4.

Amongst 18 case precise studies, bias risk was shared among the included studies
between high risk of bias and low risk of bias for items present for the SYRCLE tool [44].
This high or great bias risk was due to the allocation concealment, unsystematic housing,
blinding, and incomplete outcome data. This is a common practice in animal studies as the
current design of protocols and reporting of animal studies are very poor [37].
3.4. Decrease in Blood Glucose Level
Hypoglycemic measures were examined in six studies [3,5,15,36,40,42]. Each of the
studies were further examined by separating them into experimental groups: negative
diabetic control at baseline and diabetic intervention group (the former was given no
intervention-SFP or NSFP); subgroups were involved in meta-analysis as well as practical
statistically significant positive effect on the studies (Figure 4). Therefore, the combined
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sizes of the studies were (mean difference 4.0 mg/dL, 95% CI −0.33–8.40 as well as the
difference in mean of 4.4 mg/dL, 95% CI −0.82–9.66) as shown in the Forest plot (Figures
4 and 5 respectively.
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Due to the large proportion of I2 value (98%) in the studies (Table 4), we explored both
the subgroup (Figure 4) and moderator (Figure 5) analyses, which proved that the investigations for meta-analysis came from a heterogeneous population. Hence, the extent of
heterogeneity was examined. The random effect model was used to assume that there was
heterogeneity in the subgroups. Consequently, the combined effect sizes in the subgroups
(AA and BB) were not used. Instead, the prediction interval was used (mean difference
4.4 mg/dL, 95% prediction interval (PI) −6.65 to 15.50 and mean difference 3.4 mg/dl, 95%
prediction interval −23.65 to 30.50) [45,49].
Due to the large proportion of I2 value (98%) in the studies (Table 4), we explored
both the subgroup (Figure 4) and moderator (Figure 5) analyses, which proved that the
investigations for meta-analysis came from a heterogeneous population. Hence, the extent
of heterogeneity was examined [45,49]. The random effect model was used to assume
that there was heterogeneity in the subgroups. Consequently, the combined effect sizes in
the subgroups (AA and BB) were not used. Instead, the prediction interval (PI) was used
(mean difference 4.4 mg/dl, 95% (PI) −6.65 to 15.50 and mean difference 3.4 mg/dl, 95%
PI −23.65 to 30.50) rather than the estimate of its confidence interval (best vital result of
‘random outcomes’ representative; once the situation needs to be presumed ‘true’, outcome
dimensions differ)
Regarding regression on moderator effect size (Figure 4), there was an observable
strong correlation among moderator as well as detected influence dimensions. These
were long-established with significant outcomes in the importance test of regression load
p < 0.05 (Table 8).
Table 8. Regression of moderator on effect size showing a model y= −3.31791 + 0.13252x and p < 0.05.
Intercept
Moderator

B
−3.31791
0.13252

SE
1.81
0.03

CI LL
−7.98
0.06

Analysis of variance

Sum of squares (Q*)

df

p

Model
Residual
Total
Combined effect size
T2 (method of
moments estimation)
R2

19.79
4.01
23.80
3.98

1
4
5

0.000
0.405
0.000

CI UL
1.34
0.21

β
0.91
Mean
square
19.79
1.00

Z-Value
−1.83
4.45

p-Value
0.067
0.000

F-Value

p-value

19.75

0.011

3.34
83.16%

This proved the value effect of the study sizes on the intervention. Furthermore,
Figure 5 presents the funnel plot for the random effect meta-analysis on the mean difference
in the decrease of blood glucose (mg/dL) based on the intervention or negative diabetic
control, indicating asymmetry in the distribution of the effect sizes. Therefore, studies of
this effect (X→Y) have been conducted in the following populations. The following weight
change and enzyme inhibition population have not been studied. Observed effects range
from −0.33 to 8.40. Effects in subgroup A “Diabetic intervention” range from −0.82 to 9.66.
(Table 8) [45].
4. Discussion
This systematic review of case-controlled animal studies examining the decrease of
blood glucose level in diabetic animals found evidence to support the notion that chitosan
nanogel can relate to mixed unripe plantain, bitter yam, and okra in controlling T2D. The
results remained similar when subgroup analysis was performed. The review questions the
single use of the SFP, the use in combination with NSFP, and without cross-linking them
with chitosan controlling T2D.
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4.1. Principal Findings
Meta-analysis of the diabetic intervention subgroup demonstrated decreased hyperglycemia against blood sugar negative regulator [11,15,36,40,42,47]. However, studies from
subgroup AA (diabetic intervention) influenced much of the bases for the overall decrease
in blood glucose level as these studies were studies which had as primary outcome measure
the decrease of blood glucose and secondary outcome measures including increase of body
weight, inhibition ofα-amylase and α-glucosidase, as well as neuropathy [11,36,47,49].
Studies of the subgroup included in the meta-analysis gave results that agreed with
the different analysis proving heterogeneity of the six studies formed the I2 value (Forest
plot, subgroup analysis, moderator analysis and publication bias analysis [45]). As a
consequence of this development, the overall combined effect sizes from the meta-analysis
(Forest plot) were not useful due to the non-homogeneous studies included (not from a
single population of population samples) [45,49].
4.2. Quality of Evidence
We reflected on the value of evidence which was reasonably low due to the following
explanations: involved investigation remained at 50% high risk of bias and 50% at low
risk of bias; with the high-risk bias coming from the designed protocol [44]. We also saw
a high level of heterogeneity among the involved investigations (diabetic intervention).
This heterogeneity could reflect the different populations being examined. For instance, the
populations of the diabetic interventions that also had weight change, enzyme inhibition,
and neuropathy were different from the population of diabetic intervention by a sustained
release-time [4,31,41,47].
Ten out of the eighteen studies included in the systematic review were studies based on
the SFP and NSFP (coco- yam, soya bean cake, cassava fibre and rice bran) [2,5,47,50], while
eight studies used only chitosan to encapsulate active bio-compounds [16,30,33,39–42].
Furthermore, investigation involved in the review lasted between three and 84 days
(three days [10,29]; five days [30]; eight days [30]; 10 days [42]; 14 days [3,32,42]; 21 days [36];
28 days [3–5,24,33,35,51]; 31 days [50], and 84 days [15]). This proved the potency and
efficacy of the intervention over both short and long durations. This meant that there was
strong effect in the intervention given to the animals.
4.3. Limitation
This review had limitations. Our search strategy could have omitted abstracts and full
text articles that were published in other languages besides English. This omission could
have affected the number of studies included in the meta-analysis and the nature of the
result with respect to a more homogeneous population [14,17].
5. Conclusions and Future Implication
As the quality of the included studies was moderately low in percentage (50%), which
means that the overall risk of bias was unclear risk (50% low risk of bias and 50% high risk
of bias), there was insufficient information provided by the study authors in their protocol,
and final outcomes ought to be inferred cautiously. However, current evidence available
does support the relation of chitosan to mixed unripe plantain, bitter yam, and okra for the
management of T2D. We recommend that high quality case-controlled animal studies are
carried out to substantiate whether chitosan nanogel should indeed be cross-linked with
the SFP for the management of T2D.
Furthermore, research efforts could be geared towards extracting the phytonutrients
contained in these food plants, concentrate and fractionate (partitioned) alike, so that
extract fractions obtained can be used to test the efficacy of these food plants either through
in vitro or in vivo experimentations.
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